The involvement of the coxsackie and adenovirus receptor (CAR), an adhesion molecule known to be the main determinant of adenovirus transduction of the cells, in cancer is currently under investigation. Recent reports suggest that CAR levels are elevated in breast cancer, and this may have an impact on its use as means of delivery for gene therapy. In this study, we show that estradiol (E 2 ) treatment of the estrogen receptor (ER)-positive breast cancer cell MCF-7 increases CAR levels and, in turn, enhances adenoviral transduction. Employing the transfection of CAR promoters in breast cancer cells, we show that this regulation of CAR expression occurs at the transcriptional level. In addition, and by chromatin immunoprecipitation, we have identified a crucial region of CAR promoter that controls E 2 responsiveness of CAR gene through the recruitment of ER. Moreover, utilizing CAR antibodies or CAR silencing by RNA interference repressed the estrogen-dependent growth of breast cancer cells, whereas the stable expression of CAR in MCF-7 or MDA-MB-231 cells led to an increased proliferation. Altogether, our data suggest that CAR is a novel estrogen-responsive gene, which is involved in the E 2 -dependent proliferation of breast cancer cells.
Introduction
The coxsackie and adenovirus receptor (CAR) is a transmembrane protein that was initially characterized by its ability to allow adenovirus attachment through cells via the interaction with the adenovirus fiber-knob protein (Bergelson et al. 1997 , Lucas et al. 2003 , Glasgow et al. 2006 . Splice variants of CAR have also been identified, which could generate soluble forms of the CAR protein that lack a transmembrane domain (exon 6) (Thoelen et al. 2001) . In normal cells, CAR is associated with tight junctions (TJs) protein complexes (Cohen et al. 2001) . CAR has recently been suspected to be involved in cancer development, but its role remains controversial. Several studies have shown that CAR expression was reduced in cancer tissues compared with normal tissues in the case of bladder, renal, and prostate cancers (Li et al. 1999 , Okegawa et al. 2000 , Okegawa et al. 2001 , Haviv et al. 2002 , Sachs et al. 2002 , Matsumoto et al. 2005 , whereas in the breast, CAR expression is increased in tumors (Martin et al. 2005) . The loss of CAR expression is also associated with increased metastasis of bladder tumors (Matsumoto et al. 2005) .
So far, very little is known about CAR expression in breast cancer biopsy, and the situation appears to be significantly different from other cancers. A study showed that CAR levels are elevated in breast cancer and increase during progression and metastasis (Martin et al. 2005) . In addition, CAR expression is correlated to estrogen receptor (ER) expression in breast cancer cells (Auer et al. 2009 ). Estrogens are potent mitogens in cancerous breast tissue (Henderson et al. 1988 , Lazennec et al. 1999 , Katzenellenbogen et al. 2000 . Studies in breast cancer tissue, both in vivo and in vitro, have shown that estrogen dramatically escalates proliferative and metastatic activity in these tumor cells. The growth of w70% of all human breast cancers is dependent upon the presence of an estradiol (E 2 )-ER complex (Santen et al. 1990 ). The genomic action of estrogen is mediated by two ERs, namely ERa and ERb (Katzenellenbogen et al. 2000) . ERa is mainly involved in the mitogenic action of estrogens, whereas ERb is rather anti-proliferative both in breast, prostate, and ovarian cancer (Lazennec et al. 2001 , Bardin et al. 2004 , Cheng et al. 2004 , Lazennec 2006 .
The aim of this study was to analyze the link between CAR and estrogen signaling in breast cancer and to determine the possible role of CAR in breast cancer and the mechanisms of regulation of CAR by estrogens. We report that the treatment of ER-positive breast cancer cells leads to an increased transduction by adenovirus, which is concomitant with an induction of CAR mRNA and protein levels. The analysis of the CAR promoter revealed that CAR regulation by estrogens occurs at the transcriptional level, through an estrogen-responsive element (ERE). Very interestingly, the blockage of CAR action was sufficient to reduce the estrogen-dependent proliferation of breast cancer cells, whereas the ectopic expression of CAR could increase the proliferation of breast cancer cells.
Materials and methods

Cell culture
MCF-7 and MDA-MB-231 cells were maintained in DMEM-F12 and supplemented with 10% FCS and gentamycin as described previously (Lazennec et al. 1996) . For infection assays, cells were seeded on 6-well plates. Before any experiment, cells were weaned off steroids by being cultured in phenol redfree DMEM/F12 that had been supplemented with 10% charcoal dextran-treated FCS (CDFCS) for 5 days.
RNA extraction and reverse transcriptase PCR
Total RNA was isolated with TRIzol reagent (Invitrogen) as described by the manufacturer. Reverse transcription was performed using random primers and Superscript II enzyme (Invitrogen). Real-time PCR quantification was then performed using a SYBR Green approach (Light Cycler; Roche), as described previously (Lucas et al. 2003) . For each sample, CAR or pS2/TFF1 mRNA levels were normalized with RS9 or Rplp0 mRNA levels (reference genes). The sequences of the oligonucleotides used were CAR (transmembrane CAR, exons 6/7, (Thoelen et al. 2001) 
Recombinant adenovirus construction, propagation, and infection
The adenoviruses encoding the b-galactosidase (Ad-GAL) or ERa (Ad-ERa) used in this study have been previously described (Lazennec et al. 1999 , Lucas et al. 2003 . Briefly, the complete coding sequences of b-galactosidase, or human ERa cDNAs, were subcloned in a pACsk12CMV5 shuttle vector.
To obtain recombinant viruses, permissive HEK-293 cells (human embryonic kidney cells) were cotransfected with pACsk12CMV5, or the recombinant pACsk12CMV5 plasmid, and with pJM17 that contains the remainder of the adenoviral genome.
In vivo recombination of the plasmids generates infectious viral particles, non-recombinant adenovirus Ad5, or recombinant adenovirus Ad-GAL and Ad-ERa. MCF-7 or MDA-MB-231 cells were infected overnight at different multiplicities of infection (MOI) in DMEM/F12 10% CDFCS. The next day, the medium was changed and the cells were let to express b-GAL for 48 h before collecting the medium.
b-Galactosidase histochemical staining assay
After 48 h of expression, infected cells were washed twice with PBS and then fixed for 5 min at 4 8C in a fixing solution (2% formaldehyde, 0.2% glutaraldehyde, and 1!PBS). Cells were washed once and incubated for 4 h at 37 8C in histochemical staining solution (5 mM K 3 Fe(CN) 6 , 5 mM K 4 Fe(CN) 6 , 2 mM MgCl 2 , 1!PBS, and 1 mg/ml X-GAL; Lucas et al. 2003) . Cells were then washed twice with PBS and observed.
Western blot experiments
Cells were harvested in Tris-glycerol buffer (Tris-HCl 50 mM, EDTA 1.5 mM, and 10% glycerol) supplemented with protease inhibitor cocktail (Roche) and were then sonicated. Protein extracts (30 mg) were subjected to SDS-PAGE protein samples under non-reducing conditions. Samples were heated normally at 95 8C for 5 min in a sample loading buffer that lacked mercaptoethanol. Western blot analyses were done using CAR antibody (sc-56892, Santa Cruz, CA, USA) and b-actin (Sigma-Aldrich). Immunoreactivity was detected with Amersham ECL system. Actin was used as a loading control.
Constructs and transient transfection
A CAR promoter corresponding to sequences -1213/-127 (pGL3-1087) has been previously described (Pong et al. 2003) . Deleted constructs of the CAR promoter (pGL3-522: -648/-127; pGL3-428: -554/-127) were cloned into pGL3 basic vectors (Promega). Site-directed mutagenesis of CAR ERE was performed with CAR-EREm primers (TCGCATCCCGTGgGCATGtcGTCAGA-GAACCTGCC) to generate pGL3-EREm construct.
The ERE-TK-LUC construct consists of two ERE in tandem upstream of TK promoters (Duong et al. 2006) . We plated 3.10 5 of steroid-weaned cells in 12-well plates in phenol red-free DMEM-F12 and supplemented with 10% CDFCS 24 h before transfection. Transfections were performed using lipofectamine according to the manufacturer's recommendations, using 2 mg of the CAR promoter pGL3-1087, luciferase reporter, or CAR promoted deleted constructs along 0.5 mg of the internal reference reporter plasmid (CMV-Gal) per well. After 6 h incubation, the medium was removed and the cells were placed into a fresh medium supplemented with a control vehicle (ethanol) or E 2 . After 24 h, cells were harvested and assayed for luciferase activity using a Centro LB960 Berthold luminometer. b-galactosidase was determined as described previously (Duong et al. 2006) .
siRNA experiments
CAR protein was knocked down by transfection of MCF-7 cells with specific siRNA (GGAAGUUCAU-CACGAUAUAUC, Eurofins) according to manufacturer's protocol. Non-targeting control siRNA (siGLO red) was purchased from Dharmacon. Protein levels were determined by western blot.
CAR stable transfectants
The stably transfected MCF-7-CAR and MDA-MB-231-CAR cell lines were obtained after transfection with the plasmid pcDNA3-hCAR (a kind gift of Dr S Hemmi), encoding the human CAR cDNA under the control of the CMV promoter. Transfected cells were then selected by G418 at a concentration of 2 mg/ml. After 2 weeks of selection, a pool of resistant cells was collected and used for further experiments.
Chromatin immunoprecipitations
These assays were conducted with some modifications from Métivier et al. (2003) , using 1.10 7 MCF-7 or MDA-MB-231 cells that were placed in DMEM/0.5% CDFCS for 3 days. Afterward, some were treated with 10 nM E 2 four different times. Following cross-linking (1.5% formaldehyde for 10 min at room temperature), cells were collected in a 1 ml collection buffer (100 mM Tris-HCl (pH 9.4) and 100 mM dithiothreitol), and incubated on ice for 10 min and subsequently at 30 8C for 10 min. Cells were then lysed in a 300 ml lysis buffer (10 mM EDTA, 50 mM Tris-HCl (pH 8.0), 1% SDS, and 0.5% Empigen BB (Sigma)). Extracts were then sonicated for 14 min using a BioRuptor apparatus (Diagenode), with 30 s on/off cycles. Following 10 min centrifugation at 10 000 g, 50 ml of the supernatants were used as inputs, and the remainder diluted threefold in IP buffer (2 mM EDTA, 100 mM NaCl, 20 mM Tris-HCl (pH 8.1), and 0.5%Triton X-100). Extracts were pre-cleared for 3 h at 4 8C with 150 ml of a 50% protein A-Sepharose bead (Amersham Pharmacia Biosciences) slurry containing 10 mg yeast tRNA (Sigma) . Following centrifugation at 800 g for 1 min, one-third of the extracts were taken for immunoprecipitation using 1mg of antibodies directed against ER (HC20, Santa Cruz) or the epitope HA (HA-probe Y11, Santa Cruz) and diluted three times in a IP buffer. Complexes were recovered by a 3 h incubation at 4 8C with 50 ml of protein A-Sepharose slurry containing 10 mg yeast tRNA. Precipitates were then serially washed, using 300 ml of washing buffers (WB) I (2 mM EDTA, 20 mM Tris-HCl (pH 8.1), 0.1% SDS, 1% Triton X-100, and 150 mM NaCl), WB II (2 mM EDTA, 20 mM Tris-HCl (pH 8.1), 0.1% SDS, 1% Triton X-100, and 500 mM NaCl), WB III (1 mM EDTA, 10 mM Tris-HCl (pH 8.1), 1% NP-40, 1% deoxycholate, and 0.25 M LiCl), and then twice with 1 mM EDTA and 10 mM Tris-HCl (pH 8.1). Precipitated complexes were removed from the beads through three sequential incubations of 10 min with 50 ml of 1% SDS and 0.1 M NaHCO 3 . Cross-linking was then reversed by an overnight incubation at 65 8C. DNA was purified with Qiaquick columns (Qiagen). Subsequent quantitative PCRs analysis used 1 ml of input material and 5 ml of chromatin immunoprecipitation (ChIP) samples and were performed on a BioRad MyiQ apparatus using Bio-Rad iQ SYBR Green supermix. The sequences of the oligonucleotides used,
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0 ). The PCR efficiency was calculated for each oligonucleotide set, using serial dilutions of inputs. Once normalized to inputs following the DCt method, the results were normalized again to the ChIP performed using the control anti-HA antibody.
Proliferation assay
MCF-7 cells that had been stably transfected with a CMV-LUC reporter were grown in 24-well plates in the presence of 10 -9 M E 2 for 4-days, and in the presence of 20 ml of whole mouse serum or E1-1 anti-CAR hybridoma supernatant (Hemmi et al. 1998) . Cells were then collected and luciferase activity was measured. Concerning wild-type MCF-7, MCF-7-CAR, MDA-MB-231, and MDA-MB-231-CAR, their proliferation was quantified by counting the cells on a cell counter.
Results E 2 increases the transduction of ER-positive breast cancer cells by adenovirus
The role and the regulation of CAR expression in breast cancer cells remain elusive. We hypothesized that estrogens, which regulate the growth of ER-positive breast cancer cells, could modify their sensitivity to adenoviral infection, through a regulation of CAR levels. To analyze whether estrogens could modify the adenoviral transduction, we pre-treated ER-positive breast cancer cells MCF-7 with E 2 for 24 h before infecting them with an adenovirus encoding b-galactosidase (Ad-GAL) at increasing MOIs. We observed that adenoviral transduction was strongly enhanced in E 2 -treated cells compared with control cells (Fig. 1A) , which suggests that E 2 modifies the expression of a factor involved in adenoviral transduction. Microscopic observation confirmed that the increased staining of the plates was the result of a higher number of infected cells (Fig. 1B) . On the other hand, ER-negative MDA-MB-231 cells were similarly infected by the virus in the absence or the presence of E 2 , demonstrating that ER was required for E 2 regulation of adenoviral transduction (Fig. 1C) .
CAR levels are up-regulated by E 2
As CAR is the main determinant of adenovirus infection, we hypothesized that its expression could be regulated by estrogens, which in turn explains the effects of E 2 on adenoviral transduction. To determine whether E 2 was modulating CAR RNA levels, we treated MCF-7 cells at different times with E 2 . We measured the levels of transmembrane CAR isoform (see Materials and methods) by real-time PCR. We observed that CAR RNA expression was induced at 8 h of E 2 treatment and returned to basal levels after 24 h ( Fig. 2A) . To ensure that the regulation of CAR RNA levels by E 2 were mediated by the ER, MCF-7 cells were cotreated for 8 h with E 2 and the pure anti-estrogen ICI 182 780 , which could strongly reduce CAR RNA induction by E 2 (Fig. 2A) . CAR levels were also induced in another ER-positive breast cancer cell line, CAMA-1, suggesting that this was not specific of MCF-7 cells (data not shown). In addition, CAR protein levels were also increased upon E 2 treatment, as shown by western blot, but this induction by E 2 returned to basal levels only at 48 h (Fig. 2B) . We performed the same analysis in the ER-negative breast cancer cell line MDA-MB-231 (Fig. 2C ) and observed that CAR protein levels were not significantly affected by E 2 in these cells. This further demonstrates that ER is necessary for CAR induction by E 2 .
CAR gene promoter is regulated by estrogens Next, we investigated the possible regulation of CAR gene promoters by estrogens in MCF-7 cells. The transfection of CAR promoter reporter gene construct showed that it was induced 1.8-fold by E 2 in MCF-7 cells (Fig. 3A) . On the contrary, in the ER-negative breast cancer cell MDA-MB-231, the CAR promoter was not induced by E 2 (Fig. 3B) , demonstrating that CAR is required for the regulation of CAR promoter by estrogens. We performed a computer analysis of the CAR promoter, and we identified four half-ERE (ER binding site) and one putative ERE (-571/-557) based on the consensus ERE sequence (Gruber et al. 2004 , O'Lone et al. 2004 ; Fig. 4A ). We used first deletion constructs of the CAR promoter (Fig. 4B) . pGL3-522 (-648/-127) construct retained E 2 inducibility, but the further deletion of 94 bp (pGL3-428, -554/-127) by removing the putative ERE was sufficient to lose the responsiveness to E 2 (Fig. 4B) . Using a point mutation construct of the ERE, we observed a strong reduction of CAR promoter induction by E 2 as well (Fig. 4B) , reinforcing the central role of this ERE sequence in modulating CAR promoter activity. To validate the functionality of CAR ERE, we performed ChIPs experiments. These experiments were performed in MCF-7 cells, which exhibit an estrogenic stimulation of CAR and pS2/TFF1 genes (Fig. 4C) . ChIPs showed an early recruitment of ERa to CAR ERE sequence in 30 min (Fig. 4D) . The kinetic of recruitment of ERa to CAR promoter was more rapid than the one observed for the pS2/TFF1 promoter, which is also in agreement with the distinct kinetics of estrogen regulation of CAR and pS2/TFF1 mRNA (Fig. 4C, D) . Finally, the ability of ERa to bind to CAR ERE sequence was also confirmed by gel shift assays (data not shown).
CAR is involved in breast cancer proliferation
As CAR expression is regulated by estrogens, we next hypothesized that CAR could be involved in the proliferation of ER-positive cells. MCF-7 cells were cultured in the presence of estrogen and treated either with control serum or anti-CAR antibody. Results showed that CAR antibody reduced half the proliferation of cancer cells in the presence of E 2 (Fig. 5A) , which suggests that upregulation of CAR by estrogen is an important step in the control of estrogen-dependent growth of ER-positive breast cancer cells. In the absence of E 2 , the CAR antibody did not significantly (2011) 18 311-321 www.endocrinology-journals.org alter cell proliferation. We used a second approach based on siRNA to demonstrate the role of CAR in MCF-7 cell proliferation. Transfection of a siRNA against CAR inhibited the induction of proliferation of MCF-7 cells by E 2 (Fig. 5B) . To further confirm the potential role of CAR in breast cancer cell proliferation, we generated a pool of stable transfectant MCF-7 cells for CAR (Fig. 5C) . When comparing the MCF-7-CAR cells to wild-type MCF-7 cells, we observed that MCF-7-CAR cells displayed a higher proliferation rate compared with wild-type MCF-7 cells, in the absence and the presence of E 2 (Fig. 5D) . Of particular note, MCF-7-CAR cells grown in the absence of E 2 had a similar proliferation as wild-type MCF-7 in the presence of E 2 . This data confirms that CAR can enhance the proliferation of breast cancer cells. To demonstrate that CAR effects were not specific to a single cell line, we also generated a CAR stable transfectant in MDA-MB-231 cells (Fig. 5E ). MDA-MB-231-CAR also displayed an enhanced proliferation compared with wild-type cells (Fig. 5F ), reinforcing the fact that CAR stimulates breast cancer cell proliferation.
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Discussion
Recent studies have highlighted the possible role of CAR in carcinogenesis. However, it remains unclear whether CAR levels are modified in breast cancer cells, and what the signals controlling its expression in such cells are. In this report, we have addressed the role of CAR in breast cancer and its regulation by estrogens.
Although most of the studies have shown that CAR levels were decreased in the aggressive forms of several cancers, including glioma and bladder cancer (Okegawa et al. 2001 , Kim et al. 2003 , the breast cancer situation seems to be different. Indeed, it was shown that CAR levels were elevated in breast cancer tissues (Martin et al. 2005) . Bruning et al. 2005 also observed in a murine model of breast cancer that CAR expression was upregulated in carcinoma compared with pre-neoplastic lesion. To date, the role of CAR in breast cancer and the factors regulating CAR expression are poorly understood. Previous studies have shown that treatment of cancer cells with histone deacetylase inhibitors upregulates CAR expression (Kitazono et al. 2001 , Hemminki et al. 2003 , Pong et al. 2003 , Okegawa et al. 2007 . Other signals such as the MAPK pathway, the action of glucocorticoids, tumour necrosis factor a, and transforming growth factor-b also modulate CAR expression (Anders et al. 2003 , Bruning & Runnebaum 2003 . Pong et al. 2006 have also reported an induction of CAR expression by the phytoestrogen genistein in bladder cells, but it remains unclear whether this occurs through ER.
CAR levels are one of the primary determinants of adenoviral transduction. In this study, we show that E 2 
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www.endocrinology-journals.org increases ER-positive breast cancer cell transduction by type 5 adenoviruses. We also observed that CAR levels were increased by E 2 in ER-positive breast cancer cells, which is in agreement with a previous study, using the ER-positive breast cancer cell line T47-D (Auer et al. 2009 ). This regulation was dependent on ERs, as E 2 had no effect on CAR levels and promoter activity in ERa-negative MDA-MB-231 breast cancer cells. CAR expression was induced both at the RNA and protein levels by E 2 . However, CAR RNA induction by E 2 was transient, whereas CAR protein induction could last for more than 24 h. This suggests that CAR RNA and protein kinetics of regulation and stability are different. It is possible that CAR protein stability is affected indirectly by E 2 through the synthesis of factors controlling its turnover, which could explain the delayed induction of CAR protein expression.
Based on the rapid increase of CAR RNA levels, we thus speculated that the regulation of CAR gene by estrogens could be the result of a direct transcriptional regulation. Transfection experiments showed that CAR promoter was directly regulated by estrogens, through an ERE located in the first 600 bp of CAR gene promoter as shown by transfection, ChIPs, and gel shift experiments. The ERE sequence found in CAR figure. (B) MCF-7 cells were transfected with pGL3-1087, pGL3-522, pGL3-428, or pGL3-EREm constructs along with CMV-GAL as a control for transfection efficiency. Cells were grown in the presence or the absence of E 2 (10 K9 M). Results show relative luciferase activities (% of values of pGL3 basic vector without E 2 ) after normalization with b-gal activity (three independent experiments). (C) MCF-7 cells were treated with control vehicle ethanol (C) or E 2 (10 K9 M) for different times. CAR (left graph) and pS2/TFF1 (right) mRNA levels were determined by real-time PCR. Results represent the mean of three independent experiments and are expressed as % of controls (C). (D) Chromatin was prepared from MCF-7 cells treated as in RT-PCR experiments, or from ER-negative MDA-MB-231 cells (MDA), which were used as a control for specific immunoprecipitation. ChIP assays were then performed using antibodies directed against ER or the epitope HA as an additional control. Specific enrichment of CAR, pS2/TFF1, and control Rplp0 promoter regions in anti-ER Chip-ped material was then evaluated by quantitative PCR, with values normalized to those obtained in samples immunoprecipitated using the control antibody (C). The regions amplified are illustrated within the schemes above each graph. Results represent the mean of three independent experiments.
Endocrine-Related Cancer (2011) 18 311-321 www.endocrinology-journals.org promoter was a palindrome non-consensus sequence with a 3 bp spacing, which is the most common situation found in genes regulated by estrogen (Gruber et al. 2004 , O'Lone et al. 2004 .
Estrogens are known to be potent mitogen signals for ER-positive breast cancer cells (Prall et al. 1998) , which could also potentially involve adhesion molecules such as CAR. It was previously shown that estrogen can modulate the expression of other adhesion molecule such as N-cadherin, which is upregulated by E 2 (MacCalman et al. 1995) , or E-cadherin that is downregulated by E 2 (Oesterreich et al. 2003) . These molecules might directly or indirectly modulate cell proliferation, notably through cell architecture reorganization.
The possible role of CAR in cancer cell proliferation remains controversial. Most studies have shown in bladder, cervical, ovary cancers, and glioma that CAR was repressing cell proliferation (Okegawa et al. 2001 , Kim et al. 2003 , Bruning & Runnebaum 2004 , Huang et al. 2005 , Wang et al. 2005 , Zhang et al. 2007 , whereas others have shown mitogenic properties for CAR in lung cancer (Qin et al. 2004 , Veena et al. 2009 ). The situation in breast cancer might be unique compared with other cancers. Indeed, it was shown that CAR antagonizes the action of apoptosis inducing agents and in turn increases breast cancer cell survival (Bruning et al. 2005) . In a similar manner, as for lung cancer in which CAR silencing reduces tumor growth (Veena et al. 2009 ), we show that CAR antibodies or CAR siRNA inhibit the estrogendependent growth of MCF-7 cells. We did not observe any sign of mortality when cells were treated with the CAR antibody, which suggests that CAR affects mainly cell proliferation than survival. In addition, we report that stable expression of CAR in MCF-7 cells enhances both the basal and the estrogen-induced proliferation of these cells. This observation suggests that CAR could confer a hormone-independent growth to ER-positive breast cancer cells. Moreover, CAR can also increase the proliferation of ERa-negative MDA-MB-231 cells, suggesting that CAR could affect different types of breast cancer cells in a similar manner. The mechanisms underlying CAR effects on proliferation in breast cancer cells remain to be investigated. We believe that cell-specific factors present in breast cancer cells, and not in cancer cells of other origins, might explain why CAR stimulates the proliferation in breast cancer cells, whereas it represses the proliferation in other cancers.
The effects of CAR on proliferation, which is mainly described as an adhesion molecule, might not be direct in breast cancer cells. CAR is a major component of TJs, as are other molecules such as occludin, claudin, tricellulin, and junction adhesion molecules (JAMs; Coyne & Bergelson 2005) . In polarized epithelial cells, CAR is detected at the apical pole of the lateral membrane, where it colocalizes with the TJ protein zonula occludens-1 (ZO-1; Cohen et al. 2001) . Recent reports suggest that TJs could regulate cell proliferation (Tsukita et al. 2008) . TJs contain aqueous pores or channels that regulate paracellular permeability and serve to divide the apical and basolateral membrane compartments. As a component of TJs, CAR could affect ionic or pH conditions around epithelial cells and in turn modulates cell proliferation (Tsukita et al. 2008) . Another hypothesis is that altering the features of cell adhesion by CAR could modify cell signaling and interaction with other cofactors that directly control the proliferation or cell architecture. Increasing evidence suggest that TJs regulate gene expression (Balda & Matter 2009) . It has been shown that the cytoplasmic plaque associated with TJs is formed by multiple adaptors, scaffold proteins, and signaling components such as GTP-binding proteins, protein kinases, and phosphatases. These proteins can in turn modulate the expression or the activity of downstream signaling molecules such as cyclins, Jun/fos, or c-myc, which are known to regulate cell cycle (Balda & Matter 2009 ). In particular, it might be possible that CAR could indirectly affect phosphorylation levels of ER, which is a known mechanism for hormone-independent proliferation of ER-positive breast cancer cells. Cell context might explain the opposite effects of CAR in breast cancer cells compared with other types of cancers. We cannot exclude the possibility that the presence of ER in breast cancer cells could enable a different network of factors susceptible to act in coordination with CAR to elicit cell proliferation.
These results, together with the up-regulation of CAR by E 2 , suggest that CAR could be one of the early events leading to the induced proliferation of breast cancer cells. Our data could open the road for novel strategies to target ER-positive breast cancers.
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